stockrow
Friday 6 November 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
70.09
1.38
+2.01%
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) EBITDA
Exelixis, Inc.'s EBITDA for fiscal 2025 was $901.2M, up 42.3% from $633.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.0B. Over the past ten years it has ranged from −$103.0M (fiscal 2015) to $901.2M (fiscal 2025) — the current reading is the highest in ten years. Exelixis, Inc. ranks 9th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $901.2M | 42.28% |
| FY2024 | $633.4M | 222.18% |
| FY2023 | $196.6M | (11.58%) |
| FY2022 | $222.4M | (25.95%) |
| FY2021 | $300.3M | 151.92% |
| FY2020 | $119.2M | (68.45%) |
| FY2019 | $377.8M | (14.86%) |
| FY2018 | $443.8M | 165.58% |
| FY2017 | $167.1M | — |
| FY2016 | −$18.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $275.4M | 7.82% |
| Jun 2026 | $255.4M | (1.12%) |
| Mar 2026 | $258.3M | 6.66% |
| Dec 2025 | $242.2M | (0.74%) |
| 43 more quarters | Free account |
Against its own ten years
Low −$103.0M
High $901.2M
Ten-year median
$222.4M
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| EXEL Exelixis, Inc. | $1.0B |
| HALO Halozyme Therapeutics, Inc. compare | $719.2M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| INSM Insmed, Inc. compare | −$531.4M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement